Pneumonia, Pneumocystis
8
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
38%
3 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
Pneumocystis Pneumonia Diagnosis in HIV- Patients
Specialized Proresolving Mediators in Pneumocystis Jirovecii Pneumonia
Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19
Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
Spirulina Supplementation and Infant Growth, Morbidity and Motor Development
Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients